Merck’s Welireg–Keytruda combination won FDA approval as an adjuvant treatment for kidney cancer patients after surgery to remove all or part of the organ, extending the checkpoint-VEGFR/HIF axis into the perioperative setting. The clearance advances a strategy that aims to reduce recurrence risk in higher-risk patients post-nephrectomy. The approval arrives as kidney cancer remains a high-priority arena for combination regimens, with developers continuing to test whether adding targeted agents to immunotherapy can deepen responses and improve durability. For Merck, the label expansion also strengthens the commercial case for both assets together rather than as standalone therapies.